ORC
LLY icon

O'Rourke & Company’s Eli Lilly LLY Stock Holding History

O'Rourke & Company’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
1,497
+74
+5% +$75.6K 0.63% 46
2026
Q1 		$1.31M Sell
1,423
-2
-0.1% -$2.03K 0.52% 50
2025
Q4 		$1.53M Buy
1,425
+6
+0.4% +$5.74K 0.6% 40
2025
Q3 		$1.08M Sell
1,419
-95
-6% -$70.7K 0.45% 50
2025
Q2 		$1.18M Sell
1,514
-48
-3% -$37.3K 0.55% 45
2025
Q1 		$1.29M Buy
1,562
+83
+6% +$69.1K 0.64% 35
2024
Q4 		$1.14M Buy
1,479
+27
+2% +$22.4K 0.56% 39
2024
Q3 		$1.29M Buy
1,452
+340
+31% +$306K 0.64% 36
2024
Q2 		$1.01M Buy
1,112
+29
+3% +$23.2K 0.57% 39
2024
Q1 		$843K Buy
1,083
+256
+31% +$182K 0.49% 48
2023
Q4 		$482K Buy
827
+340
+70% +$198K 0.31% 65
2023
Q3 		$262K Hold
487
– – 0.19% 107
2023
Q2 		$228K Buy
+487
New +$204K 0.16% 125
2023
Q1 		– Sell
-787
Closed -$288K – 133
2022
Q4 		$288K Buy
+787
New +$279K 0.23% 101

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

O'Rourke & Company's LLY Position: Q2 2026 in Review

O'Rourke & Company increased its Eli Lilly (LLY) stake by 5.2% in Q2 2026, buying an estimated $75.6K and bringing the position to 1,497 shares worth $1.8M. The position accounts for 0.63% of the portfolio, ranked #46.

O'Rourke & Company first reported a position in LLY in Q4 2022 and has held it in 14 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • O'Rourke & Company held 1,497 shares of Eli Lilly worth $1.8M as of Q2 2026.
  • O'Rourke & Company bought 74 Eli Lilly shares in Q2 2026, an estimated $75.6K.
  • Eli Lilly made up 0.63% of O'Rourke & Company's portfolio in Q2 2026, its #46 holding.
  • O'Rourke & Company first reported a position in Eli Lilly in Q4 2022 and has held it in 14 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on O'Rourke & Company's 13F filing for Q2 2026, filed 14 Aug 2026.